Patent · US Active

Anti-PLGF antibody

US7875704B2 · kind B2 · utility

4Cited by
3References
17Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMar 24, 2006
Grant dateJan 25, 2011
Priority date
Expiry dateApr 10, 2027

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/24
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.